Nasdaq · CIK 0001534133
CALC CalciMedica, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $1.27 on Oct 9, 2026, 0% from the 52-week low and -96% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
CALCOct 9, 2026 · close 1.27
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at CalciMedica, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $7,675 2,500 shares | +3% | +124% from low-36% from high | |
| 28Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $9,105 3,400 shares | +4% | +99% from low-43% from high | |
| 31Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $16k 5,000 shares | +7% | +122% from low-36% from high | |
| 24Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $7,378 2,343 shares | +3% | +150% from low-28% from high | |
| 44Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $29k 10,000 shares | +16% | +91% from low-45% from high | |
| 39Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $9,797 3,508 shares | +6% | +95% from low-44% from high | |
| 44Moderate | Sudarshan Hebbar Chief Medical Officer buy | $27k 9,563 shares | +18% | +94% from low-44% from high | |
| 39Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $8,230 3,000 shares | +6% | +94% from low-44% from high | |
| 39Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $15k 5,076 shares | +10% | +103% from low-42% from high | |
| 34Weak | Sudarshan Hebbar Chief Medical Officer buy | $16k 5,976 shares | +13% | +83% from low-48% from high | |
| 42Moderate | Kenneth A. Stauderman Chief Scientific Officer buy | $3,960 1,000 shares | +8% | +159% from low-26% from high | |
| 35Weak | Kenneth A. Stauderman Chief Scientific Officer sell | $3,650 1,000 shares | -100% | +166% from low-24% from high | |
| 39Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $5,663 1,500 shares | +3% | +164% from low-24% from high | |
| 43Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $5,055 1,500 shares | +3% | +144% from low-30% from high | |
| 59Moderate | A. Rachel Leheny CHIEF EXECUTIVE OFFICER buy | $3,400 1,000 shares | +40% | +144% from low-30% from high | |
| 43Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $5,760 2,000 shares | +5% | +110% from low-40% from high | |
| 38Weak | Robert N Wilson director buy | $13k 4,500 shares | +1% | +110% from low-40% from high | |
| 46Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $16k 6,500 shares | +17% | +62% from low-54% from high | |
| 56Moderate | A. Rachel Leheny CHIEF EXECUTIVE OFFICER buy | $6,175 2,500 shares | - | +62% from low-54% from high | |
| 46Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $8,024 5,000 shares | +15% | +13% from low-68% from high | |
| 56Moderate | Kenneth A. Stauderman Chief Scientific Officer buy | $1,850 1,000 shares | - | +9% from low-69% from high | |
| 56Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $6,483 4,500 shares | +16% | 0% from low-71% from high | |
| 70Notable | Stephen Bardin Chief Financial Officer buy | $3,005 2,000 shares | +200% | 0% from low-71% from high | |
| 42Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $9,250 5,000 shares | +21% | +22% from low-64% from high | |
| 41Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $18k 10,100 shares | +76% | +14% from low-66% from high | |
| 38Weak | Stephen Bardin Chief Financial Officer buy | $1,690 1,000 shares | +3% | +16% from low-66% from high | |
| 23Weak | Fred A Middleton director, owner buy | $13k 4,800 shares | +15% | - | |
| 23Weak | Eric W Roberts CHIEF BUSINESS OFFICER buy | $8,040 3,000 shares | - | - | |
| 56Moderate | Fred A Middleton director, owner buy | $404k 107,744 shares | +920% | - | |
| 40Moderate | Sanderling Venture Partners VI Co Investment Fund LP owner buy | $329k 87,744 shares | +12% | - | |
| 45Moderate | Robert N Wilson director buy | $200k 53,333 shares | +15% | - | |
| 48Moderate | Eric W Roberts CHIEF BUSINESS OFFICER buy | $200k 53,333 shares | +48% | - | |
| 51Moderate | A. Rachel Leheny CHIEF EXECUTIVE OFFICER buy | $75k 20,000 shares | +18% | - |
Transactions
The last 85 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Allan Shaw director | AGrant or award Director Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | 7 d ago |
| Oct 1, 2026 | Robert N Wilson director | AGrant or award Director Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | 7 d ago |
| Oct 1, 2026 | Frederic Guerard director | AGrant or award Director Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | 7 d ago |
| Oct 1, 2026 | Evgeny Zaytsev director | AGrant or award Director Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | 7 d ago |
| Oct 1, 2026 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | 7 d ago |
| Sep 24, 2026 | Stephen Bardin Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +190,000 | $0.00 | $0 | 190,000 | 14 d ago |
| Sep 24, 2026 | A. Rachel Leheny CHIEF EXECUTIVE OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +360,000 | $0.00 | $0 | 360,000 | 14 d ago |
| Sep 24, 2026 | Sudarshan Hebbar Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | 14 d ago |
| Sep 24, 2026 | Kenneth A. Stauderman Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +180,000 | $0.00 | $0 | 180,000 | 14 d ago |
| Oct 13, 2025 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +937 | $0.00 | $0 | 937 | Oct 14, 2025 |
| Sep 18, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +2,500 | $3.07 | $7,675 | 84,150 | Sep 22, 2025 |
| Sep 15, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +3,400 | $2.68 | $9,105 | 81,650 | Sep 17, 2025 |
| Sep 12, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +5,000 | $3.12 | $16k | 78,250 | Sep 15, 2025 |
| Sep 9, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +2,343 | $3.15 | $7,378 | 73,250 | Sep 11, 2025 |
| Aug 28, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +9,200 | $2.86 | $26k | 70,107 | Sep 2, 2025 |
| Aug 29, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +800 | $2.74 | $2,192 | 70,907 | Sep 2, 2025 |
| Aug 21, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +3,508 | $2.79 | $9,797 | 60,907 | Aug 25, 2025 |
| Aug 19, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +1,000 | $2.79 | $2,790 | 55,399 | Aug 21, 2025 |
| Aug 19, 2025 | Sudarshan Hebbar Chief Medical Officer | POpen-market purchase Common Stock | +9,563 | $2.82 | $27k | 61,539 | Aug 21, 2025 |
| Aug 20, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +2,000 | $2.72 | $5,440 | 57,399 | Aug 21, 2025 |
| Aug 20, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | MOption exercise Common Stock | +15,000 | $1.53 | $23k | 179,706 | Aug 21, 2025 |
| Aug 20, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | MOption exercise Employee Stock Option (Right to Buy)derivative | -15,000 | $1.53 | $23k | 57,750 | Aug 21, 2025 |
| Aug 15, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +5,076 | $2.90 | $15k | 54,399 | Aug 19, 2025 |
| Aug 14, 2025 | Sudarshan Hebbar Chief Medical Officer | POpen-market purchase Common Stock | +1,584 | $2.59 | $4,095 | 47,584 | Aug 18, 2025 |
| Aug 15, 2025 | Sudarshan Hebbar Chief Medical Officer | POpen-market purchase Common Stock | +4,392 | $2.79 | $12k | 51,976 | Aug 18, 2025 |
| Jul 25, 2025 | Kenneth A. Stauderman Chief Scientific Officer | SOpen-market sale Common Stockindirect: By Spouse | -1,000 | $3.65 | $3,650 | 0 | Jul 29, 2025 |
| Jul 28, 2025 | Kenneth A. Stauderman Chief Scientific Officer | POpen-market purchase Common Stock | +1,000 | $3.96 | $3,960 | 12,944 | Jul 29, 2025 |
| Jul 22, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +1,500 | $3.78 | $5,663 | 49,323 | Jul 23, 2025 |
| Jul 21, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +1,500 | $3.37 | $5,055 | 47,823 | Jul 22, 2025 |
| Jul 21, 2025 | A. Rachel Leheny CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stockindirect: By Scheibler-Leheny Family Living Trust | +1,000 | $3.40 | $3,400 | 3,500 | Jul 21, 2025 |
| Jul 18, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +2,000 | $2.88 | $5,760 | 46,323 | Jul 18, 2025 |
| Jul 18, 2025 | Robert N Wilson director | POpen-market purchase Common Stock | +4,500 | $2.87 | $13k | 422,029 | Jul 18, 2025 |
| Jul 14, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +6,500 | $2.43 | $16k | 44,323 | Jul 16, 2025 |
| Jul 14, 2025 | A. Rachel Leheny CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stockindirect: By Scheibler-Leheny Family Living Trust | +2,500 | $2.47 | $6,175 | 2,500 | Jul 15, 2025 |
| Jul 9, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +5,000 | $1.60 | $8,024 | 37,823 | Jul 10, 2025 |
| Jul 1, 2025 | Kenneth A. Stauderman Chief Scientific Officer | POpen-market purchase Common Stockindirect: By Spouse | +1,000 | $1.85 | $1,850 | 1,000 | Jul 2, 2025 |
| Jun 26, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +4,500 | $1.44 | $6,483 | 32,823 | Jun 27, 2025 |
| Jun 24, 2025 | A. Rachel Leheny CHIEF EXECUTIVE OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +77,625 | $0.00 | $0 | 77,625 | Jun 26, 2025 |
| Jun 24, 2025 | Michael J. Dunn President and COO | AGrant or award Employee Stock Option (Right to Buy)derivative | +47,125 | $0.00 | $0 | 47,125 | Jun 26, 2025 |
| Jun 24, 2025 | Frederic Guerard director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +72,750 | $0.00 | $0 | 72,750 | Jun 26, 2025 |
| Jun 24, 2025 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Kenneth A. Stauderman Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +47,125 | $0.00 | $0 | 47,125 | Jun 26, 2025 |
| Jun 24, 2025 | Allan Shaw director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Sudarshan Hebbar Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +83,300 | $0.00 | $0 | 83,300 | Jun 26, 2025 |
| Jun 24, 2025 | Robert N Wilson director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Fred A Middleton director, owner | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 26, 2025 | Stephen Bardin Chief Financial Officer | POpen-market purchase Common Stockindirect: See Footnote | +2,000 | $1.50 | $3,005 | 3,000 | Jun 26, 2025 |
| Jun 24, 2025 | Robert N Wilson director | AGrant or award Director Stock Option (Right to Buy)derivative | +12,031 | $0.00 | $0 | 12,031 | Jun 26, 2025 |
| Jun 24, 2025 | Allan Shaw director | AGrant or award Director Stock Option (Right to Buy)derivative | +8,594 | $0.00 | $0 | 8,594 | Jun 26, 2025 |
| Jun 24, 2025 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +4,166 | $0.00 | $0 | 4,166 | Jun 26, 2025 |
| Jun 24, 2025 | Fred A Middleton director, owner | AGrant or award Director Stock Option (Right to Buy)derivative | +6,562 | $0.00 | $0 | 6,562 | Jun 26, 2025 |
| Jun 24, 2025 | Frederic Guerard director | AGrant or award Director Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jun 26, 2025 |
| Jun 24, 2025 | Robert N Wilson director | AGrant or award Director Stock Option (Right to Buy)derivative | +36,562 | $0.00 | $0 | 36,562 | Jun 26, 2025 |
| Jun 24, 2025 | Allan Shaw director | AGrant or award Director Stock Option (Right to Buy)derivative | +26,250 | $0.00 | $0 | 26,250 | Jun 26, 2025 |
| Jun 24, 2025 | Fred A Middleton director, owner | AGrant or award Director Stock Option (Right to Buy)derivative | +19,687 | $0.00 | $0 | 19,687 | Jun 26, 2025 |
| Jun 24, 2025 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 26, 2025 |
| Jun 24, 2025 | Frederic Guerard director | AGrant or award Director Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 26, 2025 |
| Jun 24, 2025 | Stephen Bardin Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Jun 24, 2025 | Fred A Middleton director, owner | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Allan Shaw director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Robert N Wilson director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 24, 2025 | Frederic Guerard director | AGrant or award Director Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jun 26, 2025 |
| Jun 11, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +5,000 | $1.85 | $9,250 | 28,323 | Jun 13, 2025 |
| Jun 5, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +5,100 | $1.70 | $8,670 | 18,323 | Jun 9, 2025 |
| Jun 6, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By FMTC Custodian - Roth IRA FBO Eric W. Roberts | +5,000 | $1.78 | $8,875 | 23,323 | Jun 9, 2025 |
| May 30, 2025 | Stephen Bardin Chief Financial Officer | POpen-market purchase Common Stock | +1,000 | $1.69 | $1,690 | 41,000 | Jun 3, 2025 |
| Apr 23, 2025 | Michael J. Dunn President and COO | AGrant or award Employee Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Apr 25, 2025 |
| Apr 23, 2025 | Kenneth A. Stauderman Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Apr 25, 2025 |
| Apr 23, 2025 | Eric W Roberts CHIEF BUSINESS OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Apr 25, 2025 |
| Apr 23, 2025 | Sudarshan Hebbar Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Apr 25, 2025 |
| Apr 23, 2025 | A. Rachel Leheny CHIEF EXECUTIVE OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +285,000 | $0.00 | $0 | 285,000 | Apr 25, 2025 |
| Apr 23, 2025 | Stephen Bardin Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Apr 25, 2025 |
| Jan 15, 2025 | Alan Glicklich director | AGrant or award Director Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jan 16, 2025 |
| Dec 6, 2024 | Fred A Middleton director, owner | POpen-market purchase Common Stock | +4,800 | $2.65 | $13k | 36,514 | Dec 6, 2024 |
| May 17, 2023 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stockindirect: By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA | +3,000 | $2.68 | $8,040 | 3,000 | Nov 6, 2024 |
| Nov 1, 2024 | Fred A Middleton director, owner | POpen-market purchase Common Stock | +20,000 | $3.75 | $75k | 31,714 | Nov 5, 2024 |
| Nov 1, 2024 | Sanderling Venture Partners VI Co Investment Fund LP owner | POpen-market purchase Common Stock | +86,867 | $3.75 | $326k | 814,300 | Nov 5, 2024 |
| Nov 1, 2024 | Fred A Middleton director, owner | POpen-market purchase Common Stockindirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P. | +86,867 | $3.75 | $326k | 814,300 | Nov 5, 2024 |
| Nov 1, 2024 | Sanderling Venture Partners VI Co Investment Fund LP owner | POpen-market purchase Common Stockindirect: By Sanderling Ventures Management VI | +877 | $3.75 | $3,289 | 22,479 | Nov 5, 2024 |
| Nov 1, 2024 | Fred A Middleton director, owner | POpen-market purchase Common Stockindirect: By Sanderling Ventures Management VI | +877 | $3.75 | $3,289 | 22,479 | Nov 5, 2024 |
| Nov 1, 2024 | Robert N Wilson director | POpen-market purchase Common Stock | +53,333 | $3.75 | $200k | 417,529 | Nov 1, 2024 |
| Nov 1, 2024 | Eric W Roberts CHIEF BUSINESS OFFICER | POpen-market purchase Common Stock | +53,333 | $3.75 | $200k | 164,706 | Nov 1, 2024 |
| Nov 1, 2024 | A. Rachel Leheny CHIEF EXECUTIVE OFFICER | POpen-market purchase Common Stock | +20,000 | $3.75 | $75k | 130,926 | Nov 1, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Stephen BardinChief Financial Officer
- Michael J. DunnPresident and COO
- Alan Glicklichdirector
- Frederic Guerarddirector
- Sudarshan HebbarChief Medical Officer
- A. Rachel LehenyCHIEF EXECUTIVE OFFICER
- Fred A Middletondirector, owner
- Eric W RobertsCHIEF BUSINESS OFFICER
- Sanderling Venture Partners VI Co Investment Fund LPowner
- Allan Shawdirector
- Kenneth A. StaudermanChief Scientific Officer
- Robert N Wilsondirector
- Evgeny Zaytsevdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.